To read the full story, subscribe or sign in.

Alphamab and JMT-Bio ink $439M antibody-drug conjugate China deal

Oct. 1, 2024

Jiangsu Alphamab Biopharmaceuticals Co. Ltd. is out-licensing its anti-HER2 bispecific antibody-drug conjugate, JSKN-003, to JMT-Bio Technology Co. for China rights in a deal worth up to ¥3.08 billion (US$439 million) plus sales royalties.

BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for Nov. 1, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 1, 2024.

Regulatory actions for Oct. 31, 2024

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...

Nanocube’s nanorobots to revolutionize cancer diagnosis, treatment

BioWorld MedTech

Nanocube Health Ltd. is developing accessible, low-cost nanorobots that could revolutionize diagnosis and treatment of hard-to-diagnose cancers, with pancreatic...

Cureverse, Angelini ink $360M deal for oral Alzheimer’s drug

BioWorld

Cureverse Inc. and Angelini Pharma SpA signed a potential $360 million deal for CV-01, an oral small-molecule candidate for Alzheimer’s disease and neurological...